IDO Pathway

Effect on Foxp3+ Tregs and Cancer

David H. Munn, Andrew L. Mellor

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Indoleamine 2,3-dioxygenase (IDO) is a metabolic pathway implicated in a number of settings that lead to acquired peripheral tolerance. IDO may also participate in the functional tolerance of the immune system towards tumors. Foxp3+ Tregs are major contributors to tumor-induced immune suppression, and emerging evidence links the IDO pathway with Treg activation. IDO-expressing dendritic cells (DCs) can drive the differentiation of naive CD4+ T cells into Foxp3+ Tregs. IDO+ DCs can also directly activate mature, preformed Tregs to mediate enhanced suppression. In experimental models, IDO also stabilizes the suppressive Treg phenotype and prevents inflammation-induced reprogramming of Tregs into pro-inflammatory (T-helper-like) cells. IDO may thus represent an important regulatory checkpoint that enhances Treg activity in tumor-bearing hosts. Drugs that target the IDO pathway may assist in reducing Treg-mediated suppression during antitumor immunotherapy.

Original languageEnglish (US)
Title of host publicationCancer Immunotherapy
Subtitle of host publicationImmune Suppression and Tumor Growth: Second Edition
PublisherElsevier Inc.
Pages583-596
Number of pages14
ISBN (Print)9780123942968
DOIs
StatePublished - Jan 1 2013

Fingerprint

Indoleamine-Pyrrole 2,3,-Dioxygenase
Neoplasms
Dendritic Cells
Peripheral Tolerance
Helper-Inducer T-Lymphocytes
Metabolic Networks and Pathways
Immunotherapy
Immune System
Theoretical Models
Inflammation
T-Lymphocytes
Phenotype

Keywords

  • Dendritic cells
  • Foxp3
  • IDO
  • Regulatory T cells
  • Tumor immunology

ASJC Scopus subject areas

  • Dentistry(all)
  • Medicine(all)

Cite this

Munn, D. H., & Mellor, A. L. (2013). IDO Pathway: Effect on Foxp3+ Tregs and Cancer. In Cancer Immunotherapy: Immune Suppression and Tumor Growth: Second Edition (pp. 583-596). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-394296-8.00033-6

IDO Pathway : Effect on Foxp3+ Tregs and Cancer. / Munn, David H.; Mellor, Andrew L.

Cancer Immunotherapy: Immune Suppression and Tumor Growth: Second Edition. Elsevier Inc., 2013. p. 583-596.

Research output: Chapter in Book/Report/Conference proceedingChapter

Munn, DH & Mellor, AL 2013, IDO Pathway: Effect on Foxp3+ Tregs and Cancer. in Cancer Immunotherapy: Immune Suppression and Tumor Growth: Second Edition. Elsevier Inc., pp. 583-596. https://doi.org/10.1016/B978-0-12-394296-8.00033-6
Munn DH, Mellor AL. IDO Pathway: Effect on Foxp3+ Tregs and Cancer. In Cancer Immunotherapy: Immune Suppression and Tumor Growth: Second Edition. Elsevier Inc. 2013. p. 583-596 https://doi.org/10.1016/B978-0-12-394296-8.00033-6
Munn, David H. ; Mellor, Andrew L. / IDO Pathway : Effect on Foxp3+ Tregs and Cancer. Cancer Immunotherapy: Immune Suppression and Tumor Growth: Second Edition. Elsevier Inc., 2013. pp. 583-596
@inbook{64bd6c43dd554d47a15dc2437410dba5,
title = "IDO Pathway: Effect on Foxp3+ Tregs and Cancer",
abstract = "Indoleamine 2,3-dioxygenase (IDO) is a metabolic pathway implicated in a number of settings that lead to acquired peripheral tolerance. IDO may also participate in the functional tolerance of the immune system towards tumors. Foxp3+ Tregs are major contributors to tumor-induced immune suppression, and emerging evidence links the IDO pathway with Treg activation. IDO-expressing dendritic cells (DCs) can drive the differentiation of naive CD4+ T cells into Foxp3+ Tregs. IDO+ DCs can also directly activate mature, preformed Tregs to mediate enhanced suppression. In experimental models, IDO also stabilizes the suppressive Treg phenotype and prevents inflammation-induced reprogramming of Tregs into pro-inflammatory (T-helper-like) cells. IDO may thus represent an important regulatory checkpoint that enhances Treg activity in tumor-bearing hosts. Drugs that target the IDO pathway may assist in reducing Treg-mediated suppression during antitumor immunotherapy.",
keywords = "Dendritic cells, Foxp3, IDO, Regulatory T cells, Tumor immunology",
author = "Munn, {David H.} and Mellor, {Andrew L.}",
year = "2013",
month = "1",
day = "1",
doi = "10.1016/B978-0-12-394296-8.00033-6",
language = "English (US)",
isbn = "9780123942968",
pages = "583--596",
booktitle = "Cancer Immunotherapy",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - IDO Pathway

T2 - Effect on Foxp3+ Tregs and Cancer

AU - Munn, David H.

AU - Mellor, Andrew L.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Indoleamine 2,3-dioxygenase (IDO) is a metabolic pathway implicated in a number of settings that lead to acquired peripheral tolerance. IDO may also participate in the functional tolerance of the immune system towards tumors. Foxp3+ Tregs are major contributors to tumor-induced immune suppression, and emerging evidence links the IDO pathway with Treg activation. IDO-expressing dendritic cells (DCs) can drive the differentiation of naive CD4+ T cells into Foxp3+ Tregs. IDO+ DCs can also directly activate mature, preformed Tregs to mediate enhanced suppression. In experimental models, IDO also stabilizes the suppressive Treg phenotype and prevents inflammation-induced reprogramming of Tregs into pro-inflammatory (T-helper-like) cells. IDO may thus represent an important regulatory checkpoint that enhances Treg activity in tumor-bearing hosts. Drugs that target the IDO pathway may assist in reducing Treg-mediated suppression during antitumor immunotherapy.

AB - Indoleamine 2,3-dioxygenase (IDO) is a metabolic pathway implicated in a number of settings that lead to acquired peripheral tolerance. IDO may also participate in the functional tolerance of the immune system towards tumors. Foxp3+ Tregs are major contributors to tumor-induced immune suppression, and emerging evidence links the IDO pathway with Treg activation. IDO-expressing dendritic cells (DCs) can drive the differentiation of naive CD4+ T cells into Foxp3+ Tregs. IDO+ DCs can also directly activate mature, preformed Tregs to mediate enhanced suppression. In experimental models, IDO also stabilizes the suppressive Treg phenotype and prevents inflammation-induced reprogramming of Tregs into pro-inflammatory (T-helper-like) cells. IDO may thus represent an important regulatory checkpoint that enhances Treg activity in tumor-bearing hosts. Drugs that target the IDO pathway may assist in reducing Treg-mediated suppression during antitumor immunotherapy.

KW - Dendritic cells

KW - Foxp3

KW - IDO

KW - Regulatory T cells

KW - Tumor immunology

UR - http://www.scopus.com/inward/record.url?scp=84902224407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902224407&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-394296-8.00033-6

DO - 10.1016/B978-0-12-394296-8.00033-6

M3 - Chapter

SN - 9780123942968

SP - 583

EP - 596

BT - Cancer Immunotherapy

PB - Elsevier Inc.

ER -